IRVINE, Calif.--(BUSINESS WIRE)--Khang & Khang LLP (the “Firm”) announces the filing of a class action lawsuit against Regulus Therapeutics Inc. (“Regulus” or the “Company”) (Nasdaq: RGLS). Investors who purchased or otherwise acquired Regulus shares between January 21, 2016 and June 27, 2016 inclusive (the “Class Period”), are encouraged to contact the firm in advance of the April 3, 2017 lead plaintiff motion deadline.
If you purchased shares of Regulus during the Class Period, please contact Joon M. Khang, Esquire, of Khang & Khang, 18101 Von Karman Avenue, 3rd Floor, Irvine, CA 92612, by telephone: (949) 419-3834, or via e-mail at firstname.lastname@example.org.
There has been no class certification in this case. Until certification occurs, you are not represented by an attorney. You may choose to take no action and remain a passive class member.
Regulus announced that it was contacted by the U.S. Food and Drug Administration ("FDA") that its new drug to treat the chronic hepatitis C virus infection will be put on clinical hold due to another case of jaundice. On January 27, 2017, Regulus disclosed that the FDA would not remove the clinical hold on RG-101 until the agency receives the last safety and efficacy information from continued clinical and pre-clinical studies.
When this information was revealed to the public, the value of Regulus fell sharply, causing investors harm.
If you have any questions concerning this notice or your rights, please contact Joon M. Khang, a prominent litigator for almost two decades, by telephone: (949) 419-3834, or by e-mail at email@example.com.
This press release may constitute Attorney Advertising in some jurisdictions.